Tonka
Well-known member
http://www.notiexpress.com.ar/news.cgi?accion=vernew&id=86938
For influenza A
A study endorsed the use of oseltamivir for influenza
06.23.2010 6:39 | The Ministry of Health claim that is effective for influenza A and does not bring large secondary problems. However, like any medicine, can not be applied to the entire population. Pregnant women, only in the last quarter. This year there were no cases in the province of Santa Fe
No cases reported so far, health authorities face the winter with the challenge of preventing the spread of H1N1 virus that transmits influenza A. Now, with one tool: the findings of a study of patients in Santa Fe and Rosario during the pandemic of last winter.
The work, carried out jointly by the Ministry of Health of the province and the Universidad Nacional del Nordeste, with the endorsement of the World Health Organization (WHO) and Pan American Health Organization (PAHO) - consisted of monitoring the effects of the drug that was used last year during the pandemic: oseltamivir, marketed under the brand name Tamiflu.
Contributed their data to study 978 people who took the drug between July and August 2009: 718 in Rosario and Santa Fe 260, 514 men and 464 women. The portfolio of Health, with technical advice from WHO and PAHO who were in the province, developed a protocol for monitoring the effects of antiviral medication. "There was a special situation of high consumption of drugs in general and of antivirals in particular, a situation that has generated the need to identify risks and enhance pharmacovigilance, can be read on the justification of the study presented yesterday.
Cappiello Minister Miguel Angel said: "There were many doubts about the drug, but the study has given us a satisfactory result with 20 percent of undesirable effects, which says the pharmacopoeia of this product internationally." And he expressed satisfaction with the results from the treatment of patients with oseltamivir: "One infers that what we are using is right and that will improve the health of one who has this virus in your body. And he will generate undesirable effects so important. "
Of the 978 cases studied, 18.5 percent had received oseltamivir prophylaxis and the rest (81.5 percent) did so within your treatment, as infected with H1N1. Another important fact: in the sample, 18 cases were pregnant women (1.8 percent) and 80 to under 15 years (8 percent), that is: between the two risk groups did not come to represent 10 percent of all cases studied, but there were unwanted effects in 20 percent of cases.
The main unwanted effects were gastrointestinal, neuropsychiatric and immunoallergic, but "mostly mild," according to Beatriz Martinelli, Director of Biochemistry and Pharmacy, Ministry of Health of the province. "There were no complications for patients in most cases. It is a drug that has high levels of security and it allows us to be confident in managing the population, "he said. But the main conclusion has to do with how to address the approach of a possible new pandemic. On the one hand, working hard on prevention and in that sense, the actions focus on risk groups: health sector actors, teenagers, children and pregnant women. Then, be clear that oseltamivir should be administered to the entire population. And, in cases of pregnant women, only in the last quarter.
Source: The Citizen
For influenza A
A study endorsed the use of oseltamivir for influenza
06.23.2010 6:39 | The Ministry of Health claim that is effective for influenza A and does not bring large secondary problems. However, like any medicine, can not be applied to the entire population. Pregnant women, only in the last quarter. This year there were no cases in the province of Santa Fe
No cases reported so far, health authorities face the winter with the challenge of preventing the spread of H1N1 virus that transmits influenza A. Now, with one tool: the findings of a study of patients in Santa Fe and Rosario during the pandemic of last winter.
The work, carried out jointly by the Ministry of Health of the province and the Universidad Nacional del Nordeste, with the endorsement of the World Health Organization (WHO) and Pan American Health Organization (PAHO) - consisted of monitoring the effects of the drug that was used last year during the pandemic: oseltamivir, marketed under the brand name Tamiflu.
Contributed their data to study 978 people who took the drug between July and August 2009: 718 in Rosario and Santa Fe 260, 514 men and 464 women. The portfolio of Health, with technical advice from WHO and PAHO who were in the province, developed a protocol for monitoring the effects of antiviral medication. "There was a special situation of high consumption of drugs in general and of antivirals in particular, a situation that has generated the need to identify risks and enhance pharmacovigilance, can be read on the justification of the study presented yesterday.
Cappiello Minister Miguel Angel said: "There were many doubts about the drug, but the study has given us a satisfactory result with 20 percent of undesirable effects, which says the pharmacopoeia of this product internationally." And he expressed satisfaction with the results from the treatment of patients with oseltamivir: "One infers that what we are using is right and that will improve the health of one who has this virus in your body. And he will generate undesirable effects so important. "
Of the 978 cases studied, 18.5 percent had received oseltamivir prophylaxis and the rest (81.5 percent) did so within your treatment, as infected with H1N1. Another important fact: in the sample, 18 cases were pregnant women (1.8 percent) and 80 to under 15 years (8 percent), that is: between the two risk groups did not come to represent 10 percent of all cases studied, but there were unwanted effects in 20 percent of cases.
The main unwanted effects were gastrointestinal, neuropsychiatric and immunoallergic, but "mostly mild," according to Beatriz Martinelli, Director of Biochemistry and Pharmacy, Ministry of Health of the province. "There were no complications for patients in most cases. It is a drug that has high levels of security and it allows us to be confident in managing the population, "he said. But the main conclusion has to do with how to address the approach of a possible new pandemic. On the one hand, working hard on prevention and in that sense, the actions focus on risk groups: health sector actors, teenagers, children and pregnant women. Then, be clear that oseltamivir should be administered to the entire population. And, in cases of pregnant women, only in the last quarter.
Source: The Citizen